To verify the regulation of IRF8 by FTO in vivo and explore the therapeutic potential of FTO inhibitor in T‐ALL, T‐ALL mouse models in Irf8+/+ and Irf8−/‐ groups were treated with FB23‐2. This evidence concerns the gene FTO and acute lymphoblastic leukemia.